Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Quiz|Articles|August 21, 2026
OncLive Weekly News Quiz (8/21/2026): Did You Miss Key Lung, Bladder, and Endometrial Cancer Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The phase 3 DESTINY-Lung04 trial (NCT05048797) compared fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) with the global standard of care as first-line therapy for HER2-mutant, nonsquamous non–small cell lung cancer (NSCLC). What did the topline results show?
Advertisement
Related to this article
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
UGN-103, a next-generation mitomycin formulation built on the ZUSDURI foundation, is supported by three-month CR and six-month DOR data from the phase 3 UTOPIA trial.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Advertisement
Advertisement
Trending on OncLive
1
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
2
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
FDA Grants Breakthrough Therapy and Fast Track Status to 68Ga-NYM096 in ccRCC
5